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Screening and Treating Hyperlipidemia  
in Patients on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib
William Torelli, DO, Thomas A. Quinn, DO, Kourtney Erickson, DO, Andrea Soliman, DO, Attiya Harit, MS, James Ross, MD 
Lehigh Valley Health Network, Allentown, Pa.
Background 
•  Tofacitinib and baricitinib (JAK inhibitors) are agents used for rheumatoid 
arthritis (RA), seronegative spondyloarthropathy (SpA), and juvenile  
idiopathic arthritis (JIA) 
•  Tocilizumab and sarilumab are biologics (IL6 inhibitors) for the management 
of inflammatory arthritis and giant cell arteritis 
•  These aforementioned drugs elevate total cholesterol and LDL levels 
•  Primary aim is to assess compliance for screening of hyperlipidemia in 
patients receiving tofacitinib, tocilizumab, sarilumab, and baricitinib at  
Lehigh Valley Health Network based on guidelines from American  
College of Rheumatology (ACR) (ARP Practice Committee, 2017) 
•  Secondary aim is to determine the frequency of patients with newly  
elevated lipids  
on these biologic agents in a private practice setting, and ensuring our 
patients are appropriately managed with statins as indicated by ASCVD 
scoring system (Goff et. all, 2013) 
Patient Population
•  Age > 18 years old 
•  Must have an indication of RA, SpA, JIA or GCA
•  Must have been treated with Tocilizumab, Tofacitinib, Sarilumab, or Baricitinib 
•  Must be a patient in Lehigh Valley Health Network (LVHN) 
Hypothesis
•  We can increase percentage of patients screened and treated for 
hypercholesterolemia after an educational session with the department  
of rheumatology and internal medicine 
Methods
•  Data reviewed on 146 patients within LVHN, from December 2018 to  
April 2018 
•  Subjects were retrieved from Epic by searching for orders of the drugs  
of interest 
•  Manual Chart Review was utilized to determine: age, gender, ethnicity, 
pathology, medication, steroid dose, additional DMARDs, medication 
duration, date of drug initiation, previous statin, baseline lipid panel, 
frequency of lipid screenings, and statin whether initiated 
Results
•  Table 1 shows demographic and clinical variables of the reviewed charts 
•  Frequency of medications used: tofacitinib (64%), tocilizumab (27%), sarilumab 
(8%), and baricitinib (0.68%) 
•  Patients examined were afflicted with the following disease processes:  
RA (90%), GCA (4%), SpA (4%), and JIA (2%)
•  Prior to the intervention , 29% of patients were on a statin and 28% had 
indications for a statin yet were not prescribed one 
•  Additionally, only 17% of patients had proper baseline lipid screening 4–8 
weeks after starting the studied drug
•  Only 13% of patients had lipid screenings every 6 months after initiation of 
the biologic agent 
•  Mean age: 56 years
•  Gender: 77% female
•  Average duration on biologic agent of interest: 760.5 days 
Conclusion
According to ACR guidelines, laboratory monitoring for 
patients on JAK and IL6 inhibition is recommended due to 
treatment related changes in neutrophils, platelets, lipids, 
and liver specific enzymes (ARP Practice Committee, 
2017). Additionally, British Society for Rheumatology (BSR) 
advocates for baseline lipid screenings, and rescreening 
every 3 months (Malaviya, 2014). 
After analyzing patients in LVHN there is room for 
improvement. Twenty eight percent of patients in the 
project have an indication for statin therapy, and are not 
being treated. Eighty two percent of patients lacked 
baseline lipid screening 4–8 weeks after starting JAK and 
IL6 inhibition. A planned intervention educating rheumatology 
and internal medicine providers on the need for improved 
adherence to the above guidelines will follow this initial 
data assessment. Data will be re-collected following the 
intervention and assessed for improvement in guideline 
compliance. After the intervention we expect to see 
increased compliance with lipid screening and management 
with patients on the studied biologic agents within LVHN.
TABLE 1
DEMOGRAPHICS DRUGS DISEASE PROCESS 
Average Age: 55.8 years Tocilizumab 27.39% (40) RA 89.72% (131)
Gender: Female 77.40% (113) Sarilumab 8.21% (12) GCA 4.10% (6)
Average days on drug: 760.5 days Baricitinib 0.684%  (1) SpA 4.10%(6)
RACE Tofacitinib 63.69% (93) JIA 2.05%(3)
Causasion: 78.76% (115) Chronic Steroids 26.71%  STATIN STATISTICS 
African American 6.84% (10)   Other DMARD 36.31% On Statin (start of study)  28.96%
Multi-racial 6.84% (10) MTX 24.65% (36) Baseline lipid level checked 17.21%
Hispanic 1.36% (2) HCQ 5.47% (8)
Frequency of Lipid Screening per 
Guidelines 13.10%
Asian 0.685% (1) LEF 4.10% (6) Appropriate Drug/Intensity  35.86 %
Other 5.47% (8) SZS 0.684 (1) Lipid Screening per guidelines 13.10%
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